172 related articles for article (PubMed ID: 28646594)
1. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
De Bruycker A; Lambert B; Claeys T; Delrue L; Mbah C; De Meerleer G; Villeirs G; De Vos F; De Man K; Decaestecker K; Fonteyne V; Lumen N; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; Duthoy W; Ost P
BJU Int; 2017 Dec; 120(6):815-821. PubMed ID: 28646594
[TBL] [Abstract][Full Text] [Related]
2. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
De Bruycker A; De Bleser E; Decaestecker K; Fonteyne V; Lumen N; De Visschere P; De Man K; Delrue L; Lambert B; Ost P
Eur Urol; 2019 May; 75(5):826-833. PubMed ID: 30503072
[TBL] [Abstract][Full Text] [Related]
3. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
[TBL] [Abstract][Full Text] [Related]
4. The relationship between local recurrences and distant metastases in prostate cancer: can
Giovacchini G; Ciarmiello A; Giovannini E; Fodor A; Cozzarini C; Mapelli P; Incerti E; Di Muzio N; Gianolli L; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):962-969. PubMed ID: 29453702
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
6. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
7. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
9. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
11. Prospective head-to-head comparison of
Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
[TBL] [Abstract][Full Text] [Related]
12. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
14. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
Evangelista L; Zattoni F; Guttilla A; Saladini G; Zattoni F; Colletti PM; Rubello D
Clin Nucl Med; 2013 May; 38(5):305-14. PubMed ID: 23486334
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
[TBL] [Abstract][Full Text] [Related]
18. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
20. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
